Why some gene therapies face sluggish launches

U.S. regulators approved Bluebird Bio’s gene therapy for patients with sickle cell disease, Lyfgenia, last December. Yet eight months into the launch, only four patients have started the $3.1 million one-time treatment for the blood disorder.